- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
622 |
R. Lazor and M.-E. Müller |
|
|
Acknowledgements The authors acknowledge Dr Samuel Rotman and Dr Igor Letovanec, Institute of Pathology, Lausanne university hospital, for providing several of the histological pictures, and Mrs Sibylle Menal for secretarial assistance.
References
1.\Davison AG, Heard BE, McAllister WAC, Turner-Warwick MEH. Cryptogenic organizing pneumonitis. Q J Med. 1983;207:382–94.
2.\Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med. 1985;312(3):152–8.
3.\American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classi cation of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.
4.\Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An of cial American Thoracic Society/ European Respiratory Society statement: update of the international multidisciplinary classi cation of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.
5.\Thomeer MJ, Costabel U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl. 2001;32:114s–8s.
6.\Xaubet A, Ancochea J, Morell F, Rodriguez-Arias JM, Villena V, Blanquer R, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):64–70.
7.\Tinelli C, De Silvestri A, Richeldi L, Oggionni T. The Italian register for diffuse in ltrative lung disorders (RIPID): a four- year report. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(Suppl 1):S4–8.
8.\Gudmundsson G, Sveinsson O, Isaksson HJ, Jonsson S, Frodadottir H, Aspelund T. Epidemiology of organising pneumonia in Iceland. Thorax. 2006;61(9):805–8.
9.\Peyrol S, Cordier JF, Grimaud JA. Intra-alveolar brosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol. 1990;137(1):155–70.
10.\Cordier JF, Peyrol S, Loire R. Bronchiolitis obliterans organizing pneumonia as a model of infammatory lung disease. In: Epler GR, editor. Diseases of the bronchioles. New York, NY: Raven Press, Ltd; 1994. p. 313–45.
11.\Colby TV. Pathologic aspects of bronchiolitis obliterans organizing pneumonia. Chest. 1992;102(1 Suppl):38S–43S.
12.\Katzenstein AL. Acute lung injury patterns: diffuse alveolar damage and bronchiolitis obliterans-organizing pneumonia. In: Katzenstein AL, editor. Katzenstein and Askin’s surgical pathology of non-neoplastic lung disease. 4th ed. Philadelphia, PA: Saunders Elsevier; 2006. p. 14–49.
13.\Katzenstein AL, Myers JL, Prophet WD, Corley LS III, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol. 1986;10(6):373–81.
14.\Cordier JF, Loire R, Brune J. Idiopathic bronchiolitis obliterans organizing pneumonia. De nition of characteristic clinical pro-les in a series of 16 patients. Chest. 1989;96(5):999–1004.
15.\Guerry-Force ML, Muller NL, Wright JL, Wiggs B, Coppin C, Pare PD, et al. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis. 1987;135(3):705–12.
16.\Muller NL, Guerry-Force ML, Staples CA, Wright JL, Wiggs B, Coppin C, et al. Differential diagnosis of bronchiolitis obliterans
with organizing pneumonia and usual interstitial pneumonia: clinical, functional, and radiologic ndings. Radiology. 1987;162(1 Pt 1):151–6.
17.\King TE Jr, Mortenson RL. Cryptogenic organizing pneumonitis. The North American experience. Chest. 1992;102(1 Suppl):8S–13S.
18.\Costabel U, Teschler H, Guzman J. Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological pro le of bronchoalveolar lavage. Eur Respir J. 1992;5(7):791–7.
19.\Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court-Fortune I, Cordier JF, et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. Am J Respir Crit Care Med. 2000;162(2 Pt 1):571–7.
20.\Cazzato S, Zompatori M, Baruzzi G, Schiattone ML, Burzi M, Rossi A, et al. Bronchiolitis obliterans-organizing pneumonia: an Italian experience. Respir Med. 2000;94(7):702–8.
21.\Nagai S, Aung H, Tanaka S, Satake N, Mio T, Kawatani A, et al. Bronchoalveolar lavage cell ndings in patients with BOOP and related diseases. Chest. 1992;102(1 Suppl):32S–7S.
22.\Mroz BJ, Sexauer WP, Meade A, Balsara G. Hemoptysis as the presenting symptom in bronchiolitis obliterans organizing pneumonia. Chest. 1997;111(6):1775–8.
23.\Lohr RH, Boland BJ, Douglas WW, Dockrell DH, Colby TV, Swensen SJ, et al. Organizing pneumonia. Features and prognosis of cryptogenic, secondary, and focal variants. Arch Intern Med. 1997;157(12):1323–9.
24.\Sveinsson OA, Isaksson HJ, Sigvaldason A, Yngvason F, Aspelund T, Gudmundsson G. Clinical features in secondary and cryptogenic organising pneumonia. Int J Tuberc Lung Dis. 2007;11(6):689–94.
25.\Oymak FS, Demirbas HM, Mavili E, Akgun H, Gulmez I, Demir R, et al. Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration. 2005;72(3):254–62.
26.\Naccache JM, Faure O, Loire R, Wiesendanger T, Cordier JF. Hypoxémie sévère avec orthodéoxie par shunt droit-gauche au cours d’une bronchiolite oblitérante avec organisation pneumonique idiopathique. Rev Mal Respir. 2000;17(1):113–6.
27.\Yamamoto M, InaY, Kitaichi M, Harasawa M, Tamura M. Clinical features of BOOP in Japan. Chest. 1992;102(1 Suppl):21S–5S.
28.\Izumi T, Kitaichi M, Nishimura K, Nagai S. Bronchiolitis obliterans organizing pneumonia. Clinical features and differential diagnosis. Chest. 1992;102(3):715–9.
29.\Lee KS, Kullnig P, Hartman TE, Muller NL. Cryptogenic organizing pneumonia: CT ndings in 43 patients. AJR Am J Roentgenol. 1994;162(3):543–6.
30.\Nishimura K, Itoh H. High-resolution computed tomographic features of bronchiolitis obliterans organizing pneumonia. Chest. 1992;102(1 Suppl):26S–31S.
31.\Alasaly K, Muller N, Ostrow DN, Champion P, FitzGerald JM. Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature. Medicine (Baltimore). 1995;74(4):201–11.
32.\Tateishi U, Hasegawa T, Seki K, Terauchi T, Moriyama N, Arai Y. Disease activity and 18F-FDG uptake in organising pneumonia: semi-quantitative evaluation using computed tomography and positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33(8):906–12.
33.\Jara-Palomares L, Gomez-Izquierdo L, Gonzalez-Vergara D, Rodriguez-Becerra E, Marquez-Martin E, Barrot-Cortes E, et al. Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia. Respir Med. 2010;104(11):1706–11.
34.\Domingo JA, Perez-Calvo JI, Carretero JA, Ferrando J, Cay A, Civeira F. Bronchiolitis obliterans organizing pneumo-
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
35 Organizing Pneumonias and Acute Interstitial Pneumonia |
623 |
|
|
nia. An unusual cause of solitary pulmonary nodule. Chest. 1993;103(5):1621–3.
35.\Murphy J, Schnyder P, Herold C, Flower C. Bronchiolitis obliterans organising pneumonia simulating bronchial carcinoma. Eur Radiol. 1998;8(7):1165–9.
36.\Yang PS, Lee KS, Han J, Kim EA, Kim TS, Choo IW. Focal organizing pneumonia: CT and pathologic ndings. J Korean Med Sci. 2001;16(5):573–8.
37.\Melloni G, Cremona G, Bandiera A, Arrigoni G, Rizzo N, Varagona R, et al. Localized organizing pneumonia: report of 21 cases. Ann Thorac Surg. 2007;83(6):1946–51.
38.\Maldonado F, Daniels CE, Hoffman EA, Yi ES, Ryu JH. Focal organizing pneumonia on surgical lung biopsy: causes, clinicoradiologic features, and outcomes. Chest. 2007;132(5):1579–83.
39.\Watanabe K, Harada T,Yoshida M, Shirakusa T, Iwasaki A,Yoneda S, et al. Organizing pneumonia presenting as a solitary nodular shadow on a chest radiograph. Respiration. 2003;70(5):507–14.
40.\Kohno N, Ikezoe J, Johkoh T, Takeuchi N, Tomiyama N, Kido S, et al. Focal organizing pneumonia: CT appearance. Radiology. 1993;189(1):119–23.
41.\Zhao F, Yan SX, Wang GF, Wang J, Lu PX, Chen B, et al. CT features of focal organizing pneumonia: an analysis of consecutive histopathologically con rmed 45 cases. Eur J Radiol. 2014;83(1):73–8.
42.\Flowers JR, Clunie G, Burke M, Constant O. Bronchiolitis obliterans organizing pneumonia: the clinical and radiological features of seven cases and a review of the literature. Clin Radiol. 1992;45(6):371–7.
43.\Bellomo R, Finlay M, McLaughlin P, Tai E. Clinical spectrum of cryptogenic organising pneumonitis. Thorax. 1991;46(8):554–8.
44.\Yousem SA, Lohr RH, Colby TV. Idiopathic bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia with unfavorable outcome: pathologic predictors. Mod Pathol. 1997;10(9):864–71.
45.\Nizami IY, Kissner DG, Visscher DW, Dubaybo BA. Idiopathic bronchiolitis obliterans with organizing pneumonia. An acute and life-threatening syndrome. Chest. 1995;108(1):271–7.
46.\Schwarz MI. Diffuse pulmonary in ltrates and respiratory failure following 2 weeks of dyspnea in a 45-year-old woman. Chest. 1993;104(3):927–9.
47.\Perez de Llano LA, Soilan JL, Garcia Pais MJ, Mata I, Moreda M, Laserna B. Idiopathic bronchiolitis obliterans with organizing pneumonia presenting with adult respiratory distress syndrome. Respir Med. 1998;92(6):884–6.
48.\Cohen AJ, King TE Jr, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med. 1994;149(6):1670–5.
49.\Romero S, Hernandez L, Gil J, Aranda I, Martin C, Sanchez-Paya J. Organizing pneumonia in textile printing workers: a clinical description. Eur Respir J. 1998;11(2):265–71.
50.\Chang J, Han J, Kim DW, Lee I, Lee KY, Jung S, et al. Bronchiolitis obliterans organizing pneumonia: clinicopathologic review of a series of 45 Korean patients including rapidly progressive form. J Korean Med Sci. 2002;17(2):179–86.
51.\Katzenstein AL, Fiorelli RF. Nonspeci c interstitial pneumonia/brosis. Histologic features and clinical signi cance. Am J Surg Pathol. 1994;18(2):136–47.
52.\Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR, et al. Idiopathic nonspeci c interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177(12):1338–47.
53.\Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society
of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–58.
54.\Kim TS, Lee KS, Chung MP, Han J, Park JS, Hwang JH, et al. Nonspeci c interstitial pneumonia with brosis: high- resolution CT and pathologic ndings. AJR Am J Roentgenol. 1998;171(6):1645–50.
55.\Lee JW, Lee KS, Lee HY, Chung MP, Yi CA, Kim TS, et al. Cryptogenic organizing pneumonia: serial high-resolution CT ndings in 22 patients. AJR Am J Roentgenol. 2010;195(4):916–22.
56.\Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD. Acute brinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med. 2002;126(9):1064–70.
57.\Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary brosis. Am J Respir Crit Care Med. 2007;176(7):636–43.
58.\Churg A, Muller NL, Silva CI, Wright JL. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of brotic interstitial pneumonias. Am J Surg Pathol. 2007;31(2):277–84.
59.\Akira M, Yamamoto S, Sakatani M. Bronchiolitis obliterans organizing pneumonia manifesting as multiple large nodules or masses. AJR Am J Roentgenol. 1998;170(2):291–5.
60.\Froudarakis M, Bouros D, Loire R, Valasiadou K, Tsiftsis D, Siafakas NM. BOOP presenting with haemoptysis and multiple cavitary nodules. Eur Respir J. 1995;8(11):1972–4.
61.\Haro M, Vizcaya M, Texido A, Aguilar X, Arevalo M. Idiopathic bronchiolitis obliterans organizing pneumonia with multiple cavitary lung nodules. Eur Respir J. 1995;8(11):1975–7.
62.\Cordier JF. Cavitary bronchiolitis obliterans organizing pneumonia. Eur Respir J. 1995;8(11):1822–3.
63.\Oikonomou A, Hansell DM. Organizing pneumonia: the many morphological faces. Eur Radiol. 2002;12(6):1486–96.
64.\Johkoh T, Muller NL, Cartier Y, Kavanagh PV, Hartman TE, Akira M, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology. 1999;211(2):555–60.
65.\Bouchardy LM, Kuhlman JE, Ball WC Jr, Hruban RH, Askin FB, Siegelman SS. CT ndings in bronchiolitis obliterans organizing pneumonia (BOOP) with radiographic, clinical, and histologic correlation. J Comput Assist Tomogr. 1993;17(3):352–7.
66.\Murphy JM, Schnyder P, Verschakelen J, Leuenberger P, Flower CD. Linear opacities on HRCT in bronchiolitis obliterans organising pneumonia. Eur Radiol. 1999;9(9):1813–7.
67.\Marchiori E, Zanetti G, Escuissato DL, Souza AS Jr, Meirelles Gde S, Fagundes J, et al. Reversed halo sign: high-resolution CT scan ndings in 79 patients. Chest. 2012;141(5):1260–6.
68.\Uner AH, Rozum-Slota B, Katzenstein AL. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener’s granulomatosis. A clinicopathologic study of 16 cases. Am J Surg Pathol. 1996;20(7):794–801.
69.\Romero S, Barroso E, Rodriguez-Paniagua M, Aranda FI. Organizing pneumonia adjacent to lung cancer: frequency and clinico-pathologic features. Lung Cancer. 2002;35(2):195–201.
70.\Cordier JF. Cryptogenic organising pneumonia. Eur Respir J. 2006;28(2):422–46.
71.\Poletti V, Cazzato S, Minicuci N, Zompatori M, Burzi M, Schiattone ML. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur Respir J. 1996;9(12):2513–6.
72.\Poulou LS, Tsangaridou I, Filippoussis P, Sidiropoulou N, Apostolopoulou S, Thanos L. Feasibility of CT-guided percutaneous needle biopsy in early diagnosis of BOOP. Cardiovasc Intervent Radiol. 2008;31(5):1003–7.
73.\Metzger F, Pernet D, Manzoni P, Ranfaing E, Dalphin JC. Apport de la biopsie pulmonaire transthoracique dans le diagnostic de pneumonie organisée. Rev Mal Respir. 2008;25(5):539–50.
624 |
R. Lazor and M.-E. Müller |
|
|
74.\Mokhtari M, Bach PB, Tietjen PA, Stover DE. Bronchiolitis obliterans organizing pneumonia in cancer: a case series. Respir Med. 2002;96(4):280–6.
75.\Zucker PK, Khouri NF, Rosenshein NB. Bleomycin-induced pulmonary nodules: a variant of bleomycin pulmonary toxicity.
Gynecol Oncol. 1987;28(3):284–91. |
|
|
76.\Cohen MB, Austin JH, Smith-Vaniz |
A, Lutzky J, |
Grimes |
MM. Nodular bleomycin toxicity. Am J Clin |
Pathol. |
|
1989;92(1):101–4. |
|
|
77.\Santrach PJ, Askin FB, Wells RJ, |
Azizkhan RG, |
Merten |
DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer. 1989;64(4):806–11.
78.\Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft- versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood. 2003;102(10):3822–8.
79.\Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1/ programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.
80.\Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 Inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–60.
81.\Pozzessere C, Bouchaab H, Jumeau R, Letovanec I, Daccord C, Bourhis J, et al. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study. ERJ Open Res. 2020;6(1):00165.
82.\Youmans AJ, Harwood J. Gross and histopathological ndings in the rst reported vaping-induced lung injury death in the united states. Am J Forensic Med Pathol. 2020;41(1):1–4.
83.\Mukhopadhyay S, Mehrad M, Dammert P, Arrossi AV, Sarda R, Brenner DS, et al. Lung biopsy ndings in severe pulmonary illness associated with E-cigarette use (vaping). Am J Clin Pathol. 2020;153(1):30–9.
84.\Kory P, Kanne JP. SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’. BMJ Open Respir Res. 2020;7(1):e000724.
85.\Vadasz I, Husain-Syed F, Dorfmuller P, Roller FC, Tello K, Hecker M, et al. Severe organising pneumonia following COVID-19. Thorax. 2021;76(2):201–4.
86.\Kim T, Son E, Jeon D, Lee SJ, Lim S, Cho WH. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with cryptogenic organizing pneumonia-like reaction: a case report. Disaster Med Public Health Prep. 2020;16:1–4.
87.\Crestani B, Valeyre D, Roden S, Wallaert B, Dalphin JC, Cordier JF, et al. Bronchiolitis obliterans organizing pneumonia syndrome primed by radiation therapy to the breast. Am J Respir Crit Care Med. 1998;158(6):1929–35.
88.\Arbetter KA, Prakash UBS, Tazelaar HD, Douglas WW. Radiation- induced pneumonitis in the “nonirradiated” lung. Mayo Clin Proc. 1999;74:27–36.
89.\Majori M, Poletti V, Curti A, Corradi M, Falcone F, Pesci A. Bronchoalveolar lavage in bronchiolitis obliterans organizing pneumonia primed by radiation therapy to the breast. J Allergy Clin Immunol. 2000;105(2 Pt 1):239–44.
90.\Morita S, Miwa S, Tsukamoto K, Tamura R, Suda T, Chida K, et al. The incidence of bronchiolitis obliterans organizing pneumonia syndrome after radiation therapy for breast cancer. Eur Respir J. 2001;18(Suppl 33):220s.
91.\Ogo E, Komaki R, Fujimoto K, Uchida M, Abe T, Nakamura K, et al. A survey of radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan. Int J Radiat Oncol Biol Phys. 2008;71(1):123–31.
92.\Katayama N, Sato S, Katsui K, Takemoto M, Tsuda T, Yoshida A, et al. Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2009;73(4):1049–54.
93.\Ogo E, Komaki R, Abe T, Uchida M, Fujimoto K, Suzuki G, et al. The clinical characteristics and non-steroidal treatment for radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Radiother Oncol. 2010;97(1):95–100.
94.\Murofushi KN, Oguchi M, Gosho M, Kozuka T, Sakurai H. Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age. Radiat Oncol. 2015;10:103.
95.\Takigawa N, Segawa Y, Saeki T, Kataoka M, Ida M, Kishino D, et al. Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys. 2000;48(3):751–5.
96.\Kano A, Ujita M, Kobayashi M, SunakawaY, Shirahama J, Harada T, et al. Radiographic and CT features of radiation-induced organizing pneumonia syndrome after breast-conserving therapy. Jpn J Radiol. 2012;30(2):128–36.
97.\Martin C, Romero S, Sanchez-Paya J, Massuti B, Arriero JM, Hernandez L. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J. 1999;13(4):727–32.
98.\Murai T, Shibamoto Y, Nishiyama T, Baba F, Miyakawa A, Ayakawa S, et al. Organizing pneumonia after stereotactic ablative radiotherapy of the lung. Radiat Oncol. 2012;7:123.
99.\Fanetti G, Bazzani F, Ferrari A, Alterio D, Donghi SM, Pounou Kamga FA, et al. Bronchiolitis obliterans organizing pneumonia after stereotactic ablative radiation therapy for lung cancer: a case report. Cancer Radiother. 2018;22(1):57–61.
100.\Mukhopadhyay S, Katzenstein AL. Pulmonary disease due to aspiration of food and other particulate matter: a clinicopathologic study of 59 cases diagnosed on biopsy or resection specimens. Am J Surg Pathol. 2007;31(5):752–9.
101.\Purcell IF, Bourke SJ, Marshall SM. Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Respir Med. 1997;91(3):175–7.
102.\Koinuma D, Miki M, Ebina M, Tahara M, Hagiwara K, Kondo T, et al. Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern Med. 2002;41(1):26–9.
103.\Kobayashi T, Kitaichi M, Tachibana K, Kishimoto Y, Inoue Y, Kagawa T, et al. A cryptogenic case of fulminant brosing organizing pneumonia. Intern Med. 2017;56(10):1185–91.
104.\Paul C, Lin-Shaw A, Joseph M, Kwan K, Sergiacomi G, Mura M. Successful treatment of brosing organising pneumonia causing respiratory failure with mycophenolic acid. Respiration. 2016;92(4):279–82.
105.\Lee J, Cha SI, Park TI, Park JY, Jung TH, Kim CH. Adjunctive effects of cyclosporine and macrolide in rapidly progressive cryptogenic organizing pneumonia with no prompt response to steroid. Intern Med. 2011;50(5):475–9.
106.\Gueta I, Shoenfeld Y, Orbach H. Intravenous immune globulins (IVIg) treatment for organizing pneumonia in a selective IgG immune deficiency state. Immunol Res. 2014;60(2–3):165–9.
107.\Justet A, Ottaviani S, Dieude P, Taille C. Tocilizumab for refractory organising pneumonia associated with Sjogren’s disease. BMJ Case Rep. 2015;2015:bcr2014209076.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
35 Organizing Pneumonias and Acute Interstitial Pneumonia |
625 |
|
|
108.\Shitenberg D, Fruchter O, Fridel L, Kramer MR. Successful rituximab therapy in steroid-resistant, cryptogenic organizing pneumonia: a case series. Respiration. 2015;90(2):155–9.
109.\Vasu TS, Cavallazzi R, Hirani A, Sharma D, Weibel SB, Kane GC. Clinical and radiologic distinctions between
secondary bronchiolitis obliterans organizing pneumo- |
|
nia and cryptogenic |
organizing pneumonia. Respir Care. |
2009;54(8):1028–32. |
|
110.\Yilmaz S, Akinci Ozyurek B, Erdogan Y, Cirit Kocer B, Demirag F, Dadali Y, et al. Retrospective evaluation of patients with organizing pneumonia: is cryptogenic organizing pneumonia different from secondary organizing pneumonia? Tuberk Toraks. 2017;65(1):1–8.
111.\Yoo JW, Song JW, Jang SJ, Lee CK, Kim MY, Lee HK, et al.
Comparison between |
cryptogenic |
organizing |
pneumonia |
and connective tissue |
disease-related |
organizing |
pneumonia. |
Rheumatology. 2011;50(5):932–8.
112.\Zuo Y, Ye L, Liu M, Li S, Liu W, Chen F, et al. Clinical signi - cance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology (Oxford). 2020;59(10):2829–37.
113.\Hoa S, Troyanov Y, Fritzler MJ, Targoff IN, Chartrand S, Mansour AM, et al. Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. Scand J Rheumatol. 2018;47(3):210–24.
114.\Chen F, Li S, Wang T, Shi J, Wang G. Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without speci c autoantibodies. Am J Med Sci. 2018;355(1):48–53.
115.\Gil B, Merav L, Pnina L, Chagai G. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol. 2016;35(8):2125–30.
116.\Chaisson NF, Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore). 2012;91(4):220–8.
117.\Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 2016;68(5):689–94.
118.\Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. Myositis autoantibodies in Korean patients with infammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;11:223.
119.\Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the ef cacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation- associated gene 5-positive dermatomyositis. Arthritis Rheum.
2020;72(3):488–98. |
|
|
120.\Romero-Bueno F, |
Diaz |
Del Campo P, Trallero-Araguas |
E, Ruiz-Rodriguez |
JC, |
Castellvi I, Rodriguez-Nieto MJ, |
et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis- associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50(4):776–90.
121.\Takada T, Suzuki E, Nakano M, Kagamu H, Tsukada H, Hasegawa T, et al. Clinical features of polymyositis/dermatomyo-
sitis with steroid-resistant interstitial lung disease. Intern Med. 1998;37(8):669–73.
122.\Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9(6):e98824.
123.\Takada K, Kishi J, Miyasaka N. Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study. Mod Rheumatol. 2007;17(2):123–30.
124.\Yokoyama Y, Furuta S, Ikeda K, Hirose K, Nakajima H. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol. 2015;25(6):888–92.
125.\Morisset J, Johnson C, Rich E, Collard HR, Lee JS. Management of myositis-related interstitial lung disease. Chest. 2016;150(5):1118–28.
126.\Hui D, Yan F, Chen RH. The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases. J Thorac Dis. 2013;5(5):613–7.
127.\Kudoh S, Azuma A,Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1829–32.
128.\Ichikawa Y, Ninomiya H, Katsuki M, Hotta M, Tanaka M, Oizumi K. Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP). Kurume Med J.
1993;40(2):65–7. |
|
|
|
129.\Stover DE, Mangino D. Macrolides: a treatment |
alterna- |
||
tive for bronchiolitis obliterans organizing pneumonia? Chest. |
|||
2005;128(5):3611–7. |
|
|
|
130.\Kastelik JA, Greenstone |
M, McGivern |
DV, |
Morice |
AH. Cryptogenic organising |
pneumonia. |
Eur Respir J. |
|
2006;28(6):1291. |
|
|
|
131.\Radzikowska E, Wiatr E, Gawryluk D, Langfort R, Bestry I, Chabowski M, et al. [Organizing pneumonia--clarithromycin treatment]. Pneumonol Alergol Pol. 2008;76(5):334–9.
132.\Radzikowska E, Wiatr E, Langfort R, Bestry I, Skoczylas A, Szczepulska-Wojcik E, et al. Cryptogenic organizing pneumonia- results of treatment with clarithromycin versus corticosteroids- observational study. PLoS One. 2017;12(9):e0184739.
133.\Radzikowska E, Rozy A, Jagus P, Wiatr E, Gawryluk D, Chorostowska-Wynimko J, et al. Cryptogenic organizing pneumonia: IL-1beta, IL-6, IL-8, and TGFbeta1 serum concentrations and response to clarithromycin treatment. Adv Exp Med Biol. 2016;911:77–85.
134.\Petitpierre N, Cottin V, Marchand-Adam S, Hirschi S, Rigaud D, Court-Fortune I, et al. A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):230–8.
135.\Onishi Y, Kawamura T, Nakahara Y, Kagami R, Sasaki S, Takahashi S, et al. Factors associated with the relapse of cryptogenic and secondary organizing pneumonia. Respir Investig. 2017;55(1):10–5.
136.\Nishino M, Mathai SK, Schoenfeld D, Digumarthy SR, Kradin RL. Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia. Hum Pathol. 2014;45(2):342–51.
137.\Saito Z, Kaneko Y, Hasegawa T, Yoshida M, Odashima K, Horikiri T, et al. Predictive factors for relapse of cryptogenic organizing pneumonia. BMC Pulm Med. 2019;19(1):10.
138.\Barroso E, Hernandez L, Gil J, Garcia R, Aranda I, Romero S. Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospital setting. Respiration. 2007;74(6):624–31.
626 |
R. Lazor and M.-E. Müller |
|
|
139.\Watanabe K, Senju S, Wen FQ, Shirakusa T, Maeda F, Yoshida M. Factors related to the relapse of bronchiolitis obliterans organizing pneumonia. Chest. 1998;114(6):1599–606.
140.\Terada T. Autopsy ndings of fatal cryptogenic organizing pneumonia. Int J Clin Exp Pathol. 2013;6(6):1128–31.
141.\Tetenta S, Chawla H, Trow LJ, Bandyopadhyay T. Cryptogenic organizing pneumonia with fatal respiratory failure. Conn Med. 2012;76(1):23–5.
142.\Lee JS, Lynch DA, Sharma S, Brown KK, Muller NL. Organizing pneumonia: prognostic implication of high-resolution computed tomography features. J Comput Assist Tomogr. 2003;27(2):260–5.
143.\Beardsley B, Rassl D. Fibrosing organising pneumonia. J Clin Pathol. 2013;66(10):875–81.
144.\Tzouvelekis A, Koutsopoulos A, Oikonomou A, Froudarakis M, Zarogoulidis P, Steiropoulos P, et al. Acute brinous and organising pneumonia: a case report and review of the literature. J Med Case Rep. 2009;3:74.
145.\Damas C, Morais A, Moura CS, Marques A. Acute brinous and organizing pneumonia. Rev Port Pneumol. 2006;12(5):615–20.
146.\Bhatti S, Hakeem A, Torrealba J, |
McMahon |
JP, Meyer |
KC. Severe acute fibrinous and |
organizing |
pneumonia |
(AFOP) causing ventilatory failure: successful treatment with mycophenolate mofetil and corticosteroids. Respir Med. 2009;103(11):1764–7.
147.\Feinstein MB, DeSouza SA, Moreira AL, Stover DE, Heelan RT, Iyriboz TA, et al. A comparison of the pathological, clinical and radiographical, features of cryptogenic organising pneumonia, acute brinous and organising pneumonia and granulomatous organising pneumonia. J Clin Pathol. 2015;68(6):441–7.
148.\Hamman L, Rich AR. Fulminating diffuse interstitial brosis of the lungs. Trans Am Clin Climatol Assoc. 1935;51:154–63.
149.\Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol. 1986;10(4):256–67.
150.\Olson J, Colby TV, Elliott CG. Hamman-Rich syndrome revisited. Mayo Clin Proc. 1990;65(12):1538–48.
151.\American Thoracic Society. Idiopathic pulmonary brosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64.
152.\Primack SL, Hartman TE, Ikezoe J, Akira M, Sakatani M, Muller NL. Acute interstitial pneumonia: radiographic and CT ndings in nine patients. Radiology. 1993;188(3):817–20.
153.\Avnon LS, Pikovsky O, Sion-Vardy N, Almog Y. Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations. Anesth Analg. 2009;108(1):232–7.
154.\Bruminhent J, Yassir S, Pippim J. Acute interstitial pneumonia (Hamman-Rich syndrome) as a cause of idiopathic acute respiratory distress syndrome. Case Rep Med. 2011;2011:628743.
155.\Goncalves-Venade G, Lacerda-Principe N, Roncon-Albuquerque R Jr, Paiva JA. Extracorporeal membrane oxygenation for refractory severe respiratory failure in acute interstitial pneumonia. Artif Organs. 2018;42(5):569–74.
156.\Johkoh T, Muller NL, Taniguchi H, Kondoh Y, Akira M, Ichikado K, et al. Acute interstitial pneumonia: thin-section CT ndings in 36 patients. Radiology. 1999;211(3):859–63.
157.\Liu XY, Jiang ZF, Zhou CJ, Peng Y. [Clinical features of 3 cases with acute interstitial pneumonia in children]. Zhonghua Er Ke Za Zhi. 2011;49(2):98–102.
158.\Parambil JG, Myers JL, Aubry MC, Ryu JH. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007;132(1):50–7.
159.\Quefatieh A, Stone CH, DiGiovine B, Toews GB, Hyzy RC. Low hospital mortality in patients with acute interstitial pneumonia. Chest. 2003;124(2):554–9.
160.\Suh GY, Kang EH, Chung MP, Lee KS, Han J, Kitaichi M, et al. Early intervention can improve clinical outcome of acute interstitial pneumonia. Chest. 2006;129(3):753–61.
161.\Vourlekis JS, Brown KK, Cool CD, Young DA, Cherniack RM, King TE, et al. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore). 2000;79(6):369–78.
162.\Bonaccorsi A, Cancellieri A, Chilosi M, Trisolini R, Boaron M, Crimi N, et al. Acute interstitial pneumonia: report of a series. Eur Respir J. 2003;21(1):187–91.
163.\Ichikado K, Johkoh T, Ikezoe J, Takeuchi N, Kohno N, Arisawa J, et al. Acute interstitial pneumonia: high-resolution CTndings correlated with pathology. AJR Am J Roentgenol. 1997;168(2):333–8.
164.\Bouros D, Nicholson AC, Polychronopoulos V, du Bois RM. Acute interstitial pneumonia. Eur Respir J. 2000;15(2):412–8.
165.\Mukhopadhyay S, Parambil JG. Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS). Semin Respir Crit Care Med. 2012;33(5):476–85.
166.\Konopka KE, Nguyen T, Jentzen JM, Rayes O, Schmidt CJ, Wilson AM, et al. Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 infection is morphologically indistinguishable from other causes of DAD. Histopathology. 2020;77(4):570–8.
167.\Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and ultrastructural ndings of fatal COVID-19 infections in Washington State: a case series. Lancet. 2020;396(10247):320–32.
168.\Vourlekis JS. Acute interstitial pneumonia. Clin Chest Med. 2004;25(4):739–47, vii.
169.\Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary brosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;10:26.
170.\Robinson DS, Geddes DM, Hansell DM, Shee CD, Corbishley C, Murday A, et al. Partial resolution of acute interstitial pneumonia in native lung after single lung transplantation. Thorax. 1996;51(11):1158–9.
171.\Ichikado K, Suga M, Muller NL, Taniguchi H, Kondoh Y, Akira M, et al. Acute interstitial pneumonia: comparison of high- resolution computed tomography ndings between survivors and nonsurvivors. Am J Respir Crit Care Med. 2002;165(11):1551–6.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/